For instance, PARP inhibitors have approval for use in patients with BRCA1/2 alterations in ovarian, prostate, breast, and pancreatic cancer; however, there is no pan‐cancer BRCA1/2 approval for these agents.26 This evidence concerns the gene BRCA1 and polyarteritis nodosa.